SPECIFIC-INHIBITION OF RE1B P52 TRANSCRIPTIONAL ACTIVITY BY THE C-TERMINAL DOMAIN OF P100/

Citation
P. Dobrzanski et al., SPECIFIC-INHIBITION OF RE1B P52 TRANSCRIPTIONAL ACTIVITY BY THE C-TERMINAL DOMAIN OF P100/, Oncogene, 10(5), 1995, pp. 1003-1007
Citations number
44
Categorie Soggetti
Genetics & Heredity",Oncology
Journal title
ISSN journal
09509232
Volume
10
Issue
5
Year of publication
1995
Pages
1003 - 1007
Database
ISI
SICI code
0950-9232(1995)10:5<1003:SORPTA>2.0.ZU;2-L
Abstract
The Rel/NF-kappa B family transcriptional factors plays an important r ole in the regulation of immune and acute phase responses. The activit y of Rel/NF-kappa B complexes is regulated by their interactions with members of the I kappa B family of inhibitors. We have previously show n that the RelB/p52 heterodimer is not effectively inhibited by any of the known I kappa B molecules: I kappa B alpha, I kappa B gamma and B cl3. Here we report that the C-terminal domain of p100 (the putative I kappa B delta) functions as a strong inhibitor of RelB/p52 transcript ional activity. In vivo interaction with I kappa B delta leads to the cytoplasmic retention and decreased DNA binding activity of RelB/p52 c omplexes. Thus, I kappa B delta is the only I kappa B molecule able to efficiently modulate the activity of RelB/p52 heterodimer, In Daudi c ells, a 46 kD protein, probably representing the C-terminal product of the proteolytic processing of p100, remains associated,vith Rel/NF-ka ppa B complexes and might have a transient regulatory function. Our re sults indicate a specific role for the putative I kappa B delta and su ggest a possible mechanism of how the truncation of the ankyrin domain of p100, found in a number of lymphoid neoplasias, might contribute t o tumorigenesis.